Endo touts financial 'flexibility' as massive opioid settlements mount industrywide

Endo is in a period of transition, with its CEO hitting the exit and a new round of opioid lawsuits expected to hit the courtroom in the coming months. With the industry favoring massive opioid settlements—and, increasingly, bankruptcy—Endo's new leader thinks the drugmaker has the formula to weather the storm.